Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): Product characteristics and preclinical profile

Haemophilia

Volumn 22, Issue 2, 2016, Pages 308-317

  Lillicrap, D ^a   Schiviz, A ^b   Apostol, C ^b   Wojciechowski, P ^c   Horling, F ^b   Lai, C K ^c   Piskernik, C ^b   Hoellriegl, W ^b   Lollar, P ^d  

^a QUEEN S UNIVERSITY   (Canada)

^b Baxalta Innovations GmbH   (Austria)

^c Baxalta US Inc   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acquired haemophilia A; Bypass agents; FVIII; FVIII inhibitors; Obizur; Recombinant porcine FVIII

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BHK CELL LINE; BLEEDING TIME; DISEASE MODEL; DOG; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG PURIFICATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; FREEZE DRYING; HEMOPHILIA A; IMMUNOGENICITY; KNOCKOUT MOUSE; MACACA FASCICULARIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; VIRAL CONTAMINATION;

EID: 84960456643     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12784     Document Type: Article

References (54)

1. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-9.
2. Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program 2006; 1: 432-7.
3. Franchini M, Mannucci PM. Acquired haemophilia A: a 2013 update. Thromb Haemost 2013; 110: 1114-20.
4. Baudo F, Collins P, Huth-Kuhne A et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012; 120: 39-46.
5. Collins PW, Blanchette VS, Fischer K et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413-20.
6. Collins P, Baudo F, Knoebl P et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood 2012; 120: 47-55.
7. Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. Semin Thromb Hemost 2012; 38: 433-46.
8. Collins PW. Management of acquired haemophilia A. J Thromb Haemost 2011; 9(Suppl 1): 226-35.
9. Collins PW, Chalmers E, Hart DP et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol 2013; 160: 153-70.
10. Huth-Kuhne A, Baudo F, Collins P et al. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94: 566-75.
11. Astermark J, Santagostino E, Keith HW. Clinical issues in inhibitors. Haemophilia 2010; 16(Suppl 5): 54-60.
12. Tjonnfjord GE, Holme PA. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors. Vasc Health Risk Manag 2007; 3: 527-31.
13. Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost 2012; 10: 1478-85.
14. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-8.
15. DeFrates SR, McDonagh KT, Adams VR. The reversal of inhibitors in congenital hemophilia. Pharmacotherapy 2013; 33: 157-64.
16. Makris M, Kasper C. The World Federation of Hemophilia guideline on management of haemophilia. Haemophilia 2013; 19: 1.
17. Prescott R, Nakai H, Saenko EL et al. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII antibodies. Blood 1997; 89: 3663-71.
18. Hay CR, Lozier JN, Lee CA et al. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey. Thromb Haemost 1996; 75: 25-9.
19. Garvey MB. Porcine factor VIII in the treatment of high-titre inhibitor patients. Haemophilia 2002; 8(Suppl 1): 5-8.
20. Kernoff PB, Thomas ND, Lilley PA, Matthews KB, Goldman E, Tuddenham EG. Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. Blood 1984; 63: 31-41.
21. Giangrande PL. Porcine factor VIII. Haemophilia 2012; 18: 305-9.
22. Lollar P, Parker CG, Tracy RP. Molecular characterization of commercial porcine factor VIII concentrate. Blood 1988; 71: 137-43.
23. Altieri DC, Capitanio AM, Mannucci PM. von Willebrand factor contaminating porcine factor VIII concentrate (Hyate:C) causes platelet aggregation. Br J Haematol 1986; 63: 703-11.
24. Gringeri A, Santagostino E, Tradati F, Giangrande PL, Mannucci PM. Adverse effects of treatment with porcine factor VIII. Thromb Haemost 1991; 65: 245-7.
25. Hay CR. Porcine factor VIII: past, present and future. Haematologica 2000; 85: 21-4.
26. US Food and Drug Administration. FDA Approves New Treatment for Rare Form of Hemophilia. www fda gov 2014 [cited 2014 Dec 3]; Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm420263.htm. Accessed December 3, 2014.
27. Healey JF, Lubin IM, Lollar P. The cDNA and derived amino acid sequence of porcine factor VIII. Blood 1996; 88: 4209-14.
28. Toschi V. OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIII. Curr Opin Mol Ther 2010; 12: 617-25.
29. Lollar P, Parker ET. Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog. J Biol Chem 1991; 266: 12481-6.
30. Doering CB, Healey JF, Parker ET, Barrow RT, Lollar P. High level expression of recombinant porcine coagulation factor VIII. J Biol Chem 2002; 277: 38345-9.
31. Kempton CL, Abshire TC, Deveras RA et al. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia 2012; 18: 798-804.
32. Lai CK, Tse A, Sivakollundu S et al. Elucidation of Structure and Functional Characteristics of OBI-1, A Recombinant, Porcine Sequence FVIII [Poster]. World Congress of the World Federation of Hemophilia (WFH), 2014.
33. Miao HZ, Sirachainan N, Palmer L et al. Bioengineering of coagulation factor VIII for improved secretion. Blood 2004; 103: 3412-19.
34. Parker ET, Healey JF, Barrow RT, Craddock HN, Lollar P. Reduction of the inhibitory antibody response to human factor VIII in hemophilia A mice by mutagenesis of the A2 domain B-cell epitope. Blood 2004; 104: 704-10.
35. Walter JD, Werther RA, Brison CM et al. Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes. Blood 2013; 122: 4270-8.
36. Takefman DM, Wong S, Maudru T, Peden K, Wilson CA. Detection and characterization of porcine endogenous retrovirus in porcine plasma and porcine factor VIII. J Virol 2001; 75: 4551-7.
37. Wojciechowski P, Lai CK, Xiong Y, Deer F. Overview of the Structure and Manufacturing Process for OBI-1: A Recombinant Porcine Sequence, Factor VIII for the Treatment of Acquired Hemophilia A [Poster]. World Congress of the World Federation of Hemophilia (WFH), 2014.
38. Mahlangu J, Andreeva T, Macfarlane D et al. Phase II open-label study evaluating hemostatic activity, pharmacokinetics and safety of recombinant porcine Factor VIII (rpFVIII, OBI-1) in hemophilia A patients with alloantibody inhibitors directed against human FVIII (hFVIII) [Oral presentation]. Blood 2007; 110: Abstract 783.
39. Kasper CK, Aledort L, Aronson D et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
40. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
41. Lundblad RL, Kingdon HS, Mann KG, White GC. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates. Thromb Haemost 2000; 84: 942-8.
42. Healey JF, Parker ET, Barrow RT, Langley TJ, Church WR, Lollar P. The comparative immunogenicity of human and porcine factor VIII in haemophilia A mice. Thromb Haemost 2009; 102: 35-41.
43. Brinks V, Weinbuch D, Baker M et al. Preclinical models used for immunogenicity prediction of therapeutic proteins. Pharm Res 2013; 30: 1719-28.
44. Parker ET, Craddock HN, Barrow RT, Lollar P. Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate: C in hemophilia A mice presensitized to human factor VIII. J Thromb Haemost 2004; 2: 605-11.
45. Bergman GE, Lollar P. Comparative immunogenicity of two forms of porcine Factor VIII in cynomolgus monkeys. Blood 2004; 104: 3079.
46. Bergman GE, Lillicrap D, Robinson P. Cross-over comparative study of tolerability, pharmacokinetics and efficacy of two forms of porcine Factor VIII in the canine model of hemophilia A. J Thromb Haemost 2005; 3(Suppl. 1): Abstract P0835.
47. Giles AR. Functional, biochemical, and morphological evaluations of experimental hemophilia therapies in animal models. Semin Hematol 1994; 31: 56-9.
48. Rawle FE, Lillicrap D. Preclinical animal models for hemophilia gene therapy: predictive value and limitations. Semin Thromb Hemost 2004; 30: 205-13.
49. Schiviz A, Piskernik C, Leidenmühler P, Muchitsch E-M, Höllriegl W. Efficacy of OBI-1, A Recombinant Porcine Sequence FVIII Product, in Animal Models of Hemophilia A [Poster]. World Congress of the World Federation of Hemophilia (WFH), 2014.
50. Connelly S, Andrews JL, Gallo AM et al. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 1998; 91: 3273-81.
51. Höllriegl W, Schiviz A, Piskernik C, Muchitsch E-M. Pharmacokinetics of OBI-1, A Recombinant Porcine Sequence FVIII Product, in Macaques and Hemophilic Dogs. World Congress of the World Federation of Hemophilia (WFH), 2014.
52. Höllriegl W, Schiviz A, Piskernik C, Dietrich B, Muchitsch E-M. Non-Clinical Development of OBI-1, A Recombinant Porcine Sequence FVIII Product [Poster]. Thrombosis and Hemostasis Summit of North America (THSNA), 2014.
53. Allacher P, Horling FM, Piskernik C, Leidenmühler P, Reipert BM. Non-Clinical Immunogenicity Assessment of A New Recombinant Porcine Sequence FVIII (OBI-1) [Poster]. World Congress of the World Federation of Hemophilia (WFH), 2014.
54. Schiviz A, Höllriegl W, Piskernik C, Leidenmühler P, Muchitsch E-M, Dietrich B. Preclinical Safety of OBI-1, A Recombinant Porcine Sequence FVIII Product [Poster]. World Congress of the World Federation of Hemophilia (WFH), 2014.